Comparison of stroke process measures and clinical outcomes between English and Non-English preferring patients.

BACKGROUND: In the United States, limited English proficiency may reduce the quality of care and worsen outcomes after stroke. The aim was to compare stroke process measures and clinical outcomes between English preferring and non-English preferring stroke patients. METHODS/MATERIALS: This single-center retrospective cohort study evaluated patients from one United States hospital with acute ischemic stroke between July 2013 and June 2022. The primary outcomes were defect-free care, a composite of 7 stroke process measures, and independent ambulation at hospital discharge. Multivariate logistic regression models quantified the association between language preference and outcomes. Secondary outcomes included individual components of defect-free care, discharge modified Rankin scale, and discharge disposition. RESULTS: There were 4,030 patients with acute ischemic stroke identified, of which 2,965 were matched with language data from the electronic medical record. There were 373 non-English preferring patients, among which 76.9% preferred Spanish and 23.1% were non-English, non-Spanish preferring. In the multivariable model, there was no significant association between non-English preference and defect-free care (OR=0.64, 95% CI=0.26-1.59) or independent ambulation at discharge (OR=0.89, 95% CI=0.67-1.17). When compared to Spanish preferring patients, non-English, non-Spanish preferring patients had more severe strokes (P<0.001) but there was no difference in defect-free care or independent ambulation after adjustment. CONCLUSION: Our results suggest that process and clinical outcomes are similar regardless of language preference; although, our data are limited by small numbers of non-English, non-Spanish preferring patients. Additional research is needed among this population.

Brivaracetam for epilepsy.

More than a third of patients with epilepsy cannot achieve freedom from seizures despite taking multiple medications. This article compares brivaracetam to levetiracetam, and provides guidelines for the safe and effective use of brivaracetam.

From refugee to pharmacist: Insights for better care.

PURPOSE: This reflection utilizing Gibb's model offers insight into the lived experience of a Vietnamese child refugee who, many years later, found herself working as a pharmacist with Afghan refugees. DESCRIPTION: Through this piece, the author describes her childhood experience with the United States (US) healthcare system as a refugee, her experience as a pharmacist caring for refugees, and explores her thoughts and feelings about the experience. ANALYSIS/INTERPRETATION: The author evaluates the positive and negative aspects of the situation and analyzes the experience to make sense of the situation. CONCLUSIONS: After reflecting on what she learned through her experience combined with findings in the literature, the author offers recommendations to pharmacists as they care for refugees, emphasizing the need for trauma-informed care for refugees with limited English language skills who are trying to navigate the complex US healthcare system. IMPLICATIONS: This piece offers insights for pharmacists caring for refugees on how to offer better care.

The Role of Clinical Pharmacists in Patient-Centric Comprehensive Multiple Sclerosis Care.

BACKGROUND: Individuals with multiple sclerosis (MS) may experience a variety of visible and invisible symptoms and, as they age, comorbidities related and unrelated to their MS. This can result in a complex medication regimen that includes disease-modifying therapies, symptom management drugs, and prescriptions for other comorbid disorders. METHODS: We reviewed the existing literature to discover how to optimally integrate neurology clinical pharmacists into the MS care team and how clinical pharmacists can directly support both providers and patients through their expertise in pharmacology and medication management. RESULTS: With approaches founded on a shared decision-making process alongside neurology providers, patients, and care partners, clinical pharmacists can help meet the complex challenges of MS care in a variety of ways. Especially within MS clinics, they are well positioned to enhance current neurology practices given their extensive training in comprehensive medication management and their ability to identify nuances in medication management to promote pharmacovigilance and patient-centered care. CONCLUSIONS: Neurology clinical pharmacists bring multifaceted medication management and patient counseling and education skills to the MS care team and can support the shared decision-making process by serving as an accessible resource for patients and clinicians. By building trusted partnerships between neurology providers and clinical pharmacists, MS care teams can achieve effective and efficient patient care. Future research should compare clinical and patient-reported outcomes between patients receiving standard care and those receiving multidisciplinary, pharmacist-integrated care.